Alzheimer’s disease has long exasperated researchers and patients alike for its seeming impossibility to be treated, let alone cured. The pile of investigational therapies that once showed theoretical promise, but failed to translate this into clinical success, is ever-growing.
This could soon change. Lecanemab, an investigational drug candidate jointly developed by Biogen and Eisai, made international headlines last September after the drug slowed cognitive decline compared to placebo for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?